Skip To Main Content
Jeanne Tie on Muck Rack

Jeanne Tie

As seen in: Nature, PLOS Medicine, Gut Journal, MDPI, The Conversation, JAMA Oncology, The New England Journal of Medicine, MedPage Today, The Lancet, Healio and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeanne

Contact Jeanne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Circulating Tumor DNA-Guided Adjuvant Chemotherapy De-Escalation for Stage 3 Colon Cancer

|
By Jeanne Tie
| Oncology Learning Network Verified
Jeanne Tie, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses findings from the DYNAMIC-III trial, which evaluated a ctDNA-guided approach to adjuvant chemotherapy in patients with stage 3 colon cancer. The trial found that tailoring treatment based on post-surgery ctDNA results significantly reduced oxaliplatin use and treatment-related toxicity, with recurrence-free survival outcomes closely matching standard management, particularly in patients with low-risk disease.
Open in Who Shared Issue with article?

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial - Nature Medicine

|
By Jeanne Tie, Jonathan M Loree, Rachel Wong, James Lynam, Belinda Lee, Lorraine A. Chantrill, Sharlene Gill, Chetan Bettegowda, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Siavash Foroughi
| Nature Verified
Abstract Adjuvant chemotherapy in stage III colon cancer provides uncertain benefit at the individual level. Circulating tumor DNA (ctDNA) may help refine risk-adjusted treatment selection. In this multicenter, randomized, phase 2/3 trial, patients with stage III colon cancer underwent ctDNA testing 5–6 weeks after surgery and were assigned (1:1) to ctDNA-guided or standard management.
Open in Who Shared Issue with article?

The emerging clinical utility of ctDNA to guide adjuvant treatment in cancer

|
By Emma Sanderson, Peter Gibbs, Jeanne Tie
| The Lancet Verified
CommentVolume 59101595Open access aDivision of Personalised Oncology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia bDepartment of Medical Oncology, Western Health, Melbourne, Victoria, Australia cFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia dDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Publication History: Received May 25, 2025; Accepted May...
Open in Who Shared Issue with article?
See all 26 licensed articles (27 Total)